Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

China · Delayed Price · Currency is CNY

27.13

+1.19 (4.59%)

At close: Feb 13, 2026

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Adsorbed Tetanus Vaccine	535.78M
Adsorbed Tetanus Vaccine Growth	15.73%
Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine	26.42M
Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine Growth	580.49%
Influenzae Type B Haemophilus Conjugate Vaccine	23.50M
Influenzae Type B Haemophilus Conjugate Vaccine Growth	-13.82%
Refined Tetanus Toxoid Original Solution	404.53K
Refined Tetanus Toxoid Original Solution Growth	127.27%
Other	2.75M
Other Growth	50.34%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	588.86M
China Growth	18.69%